The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Sponsor
Third Military Medical University
Study ID
NCT02733107
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib, 250mg daily, po, continue until disease progression
  • Etoposide — DRUG
    Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression

Study Details

The development of anti-angiogenesis drugs has led to renewed enthusiasm in lung cancer treatments. Apatinib is a tyrosine kinase inhibitor which selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR-2). Etoposide is an oral preparation for lung cancer which is recommended by NCCN guideline. The investigators wondered whether these two drugs have synergistic effects when treating advanced non-small cell lung cancer patients who failed to previous at least 2nd line treatments. Thus, the aim of this trial is to investigate the efficacy and safety of apatinib combined with etoposide in heavily pretreated advanced non-small cell lung cancer.

Key Dates

Start date
Mar 31, 2016
Status verified
Apr 2016
Primary completion
Dec 31, 2019
Completion
Dec 31, 2020

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Apatinib+Etoposide
    Apatinib combined with Etoposide

Primary Outcome Measure

Progression free survival [ Time Frame: evaluated in 24 months since the treatment began ]

Central Contacts

Related Studies